Lord, Abbett & Co
TXMD icon

Lord, Abbett & Co’s TherapeuticsMD TXMD Stock Holding History

Lord, Abbett & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-17,311
Closed -$4.02M – 984
2014
Q3 		$4.02M Buy
17,311
+5,543
+47% +$1.4M 0.01% 778
2014
Q2 		$2.6M Buy
11,768
+3,068
+35% +$683K 0.01% 910
2014
Q1 		$2.75M Buy
+8,700
New +$2.77M 0.01% 890

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Lord, Abbett & Co's TXMD Position: Q4 2014 in Review

Lord, Abbett & Co sold out of TherapeuticsMD (TXMD) in Q4 2014, closing a stake of 17,311 shares — an estimated $4.02M sold.

Lord, Abbett & Co first reported a position in TXMD in Q1 2014 and held it in 3 quarters. The position peaked at $4.02M in Q3 2014. 81 funds tracked by Wall St. Rank hold TXMD as of Q4 2014.

  • Lord, Abbett & Co reported no remaining TherapeuticsMD position as of Q4 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 17,311 TherapeuticsMD shares in Q4 2014, an estimated $4.02M.
  • Lord, Abbett & Co first reported a position in TherapeuticsMD in Q1 2014 and held it in 3 quarters.
  • Lord, Abbett & Co's TherapeuticsMD position peaked at $4.02M in Q3 2014.
  • 81 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2014.

Based on Lord, Abbett & Co's 13F filing for Q4 2014, filed 13 Feb 2015.